Codes, payment rates, coverage policy, and whose budget it comes from — chronic subjective tinnitus neuromodulation

1. Summary

This repo's typed hcpcs/payment/coverage connectors have no local CMS cache on this machine, so every code probed this pass returned unconfirmed for that reason alone — a structural gap in this environment, not a finding about any code. Two independent, non-affiliated commercial payers' own published coverage policies — Aetna and Blue Cross Blue Shield of North Carolina — each state directly that no HCPCS code exists specifically for a tinnitus-masking or bimodal-neuromodulation device, and both name HCPCS S8948 among the generic codes their policies discuss in connection with tinnitus treatment [1][2]. No Medicare National Coverage Determination text was retrieved this pass for any tinnitus-device category — www.cms.gov blocked every retrieval attempt — but a general Medicare regulation excluding hearing aids from coverage was independently confirmed live via this repo's regulation connector [5], the same product category commercial payers place tinnitus-masking technology in. Separately, federal procurement regulation confirms that GSA has delegated authority to the VA specifically to run its own Federal Supply Schedule for medical equipment [4], and the VA's own medical-benefits regulation lists hearing aids as an authorized benefit [3] — two structural facts about a federal budget channel, independent of any manufacturer's own account of a specific contract. Whether that channel currently reaches this domain's founding device rests, in this pass as in the domain dossier, on manufacturer press materials this report could not independently re-source with an identifier of the kind this report's citation rules require (§5).

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

What this environment could check directly, and what it could not

connectors hcpcs, connectors payment and connectors coverage each require a local CMS cache file (data/hcpcs_level_ii.csv, data/hcpcs_payment_rates.csv, data/medicare_coverage_policies.csv) that is absent on this machine. Probing any code — including the codes named below by payer policy text — returns the connector's own unconfirmed result citing the missing file, never a result about the code itself. This report therefore carries no connector-verified HCPCS payment rate or Medicare coverage determination; everything about codes and coverage below comes from directly retrieved payer and federal-regulation text instead.

Absence of a dedicated device code

Blue Cross Blue Shield of North Carolina's own medical policy states plainly, of tinnitus-masking devices as a device category: "Tinnitus-masking devices represent a piece of durable medical equipment. There is currently no specific HCPCS code describing these devices," and separately names HCPCS S8948 among the codes its policy discusses for tinnitus treatment [1]. Aetna's own coding table for its tinnitus-treatments policy independently reaches the same conclusion for this domain's founding device by name: its "not covered" HCPCS list includes E0720 among a broader set of codes tied to tinnitus-adjacent technologies, and its device-specific line reads, verbatim: "Lenire device (bi-modal neuromodulation) – no specific code" [2]. Because two independent, non-affiliated payers each state — in their own words, for their own coding tables — that no HCPCS code exists for this device category, the absence of a dedicated code is stated here without a marker; the Lenire-specific naming is Aetna's alone and carries [single-source].

Coverage determination — commercial payers

Aetna's policy classifies "Lenire device (bi-modal neuromodulation)" under interventions where, in the bulletin's own language, "the effectiveness of these approaches has not been established," alongside tinnitus retraining therapy and tinnitus maskers/hearing-aid combinations generally [2] [single-source] — no second commercial payer's policy naming Lenire specifically was located or retrieved this pass. Blue Cross Blue Shield of North Carolina reaches a parallel but independently-worded determination for the broader device category, not naming Lenire: "Treatment of tinnitus with any of the following therapies is considered investigational: tinnitus maskers, customized sound therapy," citing that the supporting randomized trials "had medium-to-high risk of bias and do not show the efficacy of masking therapy" [1] [single-source]. Cigna's and UnitedHealthcare's tinnitus-related coverage policies were searched for but not retrieved this pass (§5).

Medicare — no device-specific text retrieved, but an adjacent statutory exclusion confirmed

A National Coverage Determination titled "Tinnitus Masking" (NCD 50.6) was located by search but its text could not be retrieved this pass: www.cms.gov returned HTTP 403 on the Medicare Coverage Database view page, on the National Coverage Determinations Manual PDF, and on a third-party PDF mirror of the same manual chapter. No finding from that NCD is reported here (§5). Separately, and confirmed live this pass via this repo's typed regulation connector against the eCFR API, 42 CFR 411.15 is a Medicare coverage-exclusion regulation that the connector confirmed "contains 'hearing aid'"; the specific hearing-aid clause's exact wording was not returned within the length the connector retrieved, so only the section's existence and confirmed subject-matter match are reported, not the clause's verbatim text [5]. This is regulatory context for the category commercial payers place tinnitus-masking technology in — it is not itself a tinnitus- or neuromodulation-specific coverage determination, and should not be read as one.

Whose budget it comes from — the VA channel's regulatory basis

Two federal regulations, both confirmed live this pass via the regulation connector, together describe a budget channel structurally distinct from the commercial/Medicare pattern above. 38 CFR 17.38(a)(1)(viii), defining the VA's medical benefits package, authorizes "eyeglasses and hearing aids as authorized under § 17.149" as part of that package [3]. 48 CFR 8.402(a) states that the Federal Supply Schedule ("Multiple Award Schedule") program is directed by GSA, and explicitly that "GSA has delegated authority to the VA to procure medical supplies under the VA Federal Supply Schedules program," and that orders issued under the VA Federal Supply Schedule program are, in the regulation's own words, "covered by this subpart" [4]. Together these establish that a VA-authorized hearing-related benefit, procured through a GSA-delegated schedule contract, is a real, regulation-defined mechanism — independent of whether any specific contractor or device currently uses it. Whether this domain's founding device does so today is addressed, and its sourcing limits stated, in §5.

Not established this pass

Payment rate for any HCPCS code named above; site-of-service payment differential; whether any Medicaid state plan or Medicare Advantage plan has issued its own coverage determination naming this device category; the GSA Federal Supply Schedule pricelist amount for any device on the schedule referenced in §3's VA discussion.

4. Sources

[1] Tinnitus Treatment — Blue Cross Blue Shield of North Carolina, medical coverage policy (last review 2025-08, day not given on the retrieved page; accessed 2026-09-01). HCPCS S8948 cited within the policy's applicable-codes list — https://www.bcbsnc.com/providers/policies-guidelines-codes/commercial/medical/updates/tinnitus-treatment [payer-policy] [2] Tinnitus Treatments — Aetna, Clinical Policy Bulletin Number 0406 (revision date not shown on the retrieved page; accessed 2026-09-01). HCPCS E0720 cited within the policy's own coding section, alongside the policy's "Lenire device (bi-modal neuromodulation) – no specific code" line — https://www.aetna.com/cpb/medical/data/400_499/0406.html [payer-policy] [3] 38 CFR 17.38, Medical benefits package — eCFR, retrieved via this repo's regulation connector (issue 2026-08-27; accessed 2026-09-01). 38 CFR 17.38 — https://www.ecfr.gov/current/title-38/chapter-I/part-17/subject-group-ECFR266d2eddfb35a72/section-17.38 [federal-registry] [4] 48 CFR 8.402, Federal Supply Schedule program — General — eCFR, retrieved via this repo's regulation connector (issue 2026-08-07; accessed 2026-09-01). 48 CFR 8.402 — https://www.ecfr.gov/current/title-48/chapter-1/subchapter-B/part-8/subpart-8.4/section-8.402 [federal-registry] [5] 42 CFR 411.15, Particular services excluded from coverage — eCFR, retrieved via this repo's regulation connector (issue 2026-08-13; accessed 2026-09-01). 42 CFR 411.15 — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-411/subpart-A/section-411.15 [federal-registry] [6] 21 CFR 874.3410, Combined acoustic and electrical external stimulation device for the relief of tinnitus — eCFR, retrieved via this repo's regulation connector (issue 2026-08-27; accessed 2026-09-01). 21 CFR 874.3410 — https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-874/subpart-D/section-874.3410 [federal-registry]

5. Sourcing & Gaps

Well established: That no HCPCS code exists specifically for a tinnitus-masking or bimodal-neuromodulation device rests on two independent, non-affiliated commercial payers' own coding tables [1][2] and is stated plainly for that reason. That 38 CFR 17.38 and 48 CFR 8.402 exist and say what they are quoted as saying rests on this repo's typed regulation connector confirming live text against the eCFR API this pass — a class-1 registry check, not a search result.

Thin: The claim that "Lenire device (bi-modal neuromodulation)" is specifically named and deemed not covered rests on Aetna's bulletin alone ([single-source]) — no second payer's policy naming the device by name was located. Blue Cross Blue Shield of North Carolina's parallel "investigational" determination for the broader device category is also [single-source], independently worded and not about the named device. 21 CFR 874.3410's relevance here is contextual (it explains why no CPT/HCPCS crosswalk existed before the product code's 2023 creation) rather than itself a reimbursement finding, and is cited on that basis alone [6].

Rescoped from class 3: None in this report. Every question addressed here — which code applies, what a named payer's policy says, what a federal regulation says — is class 1 (a registry record) or a directly quoted class-2/payer-policy document, not a question about what a person would do.

Out of scope: CPT and CPT Category III code numbers and descriptors, per the manifest's scope note — even where a retrieved source (Aetna, Blue Cross Blue Shield of North Carolina) also listed CPT/Category III codes alongside the HCPCS codes reported here, those codes are omitted entirely rather than partially reproduced. Non-US coverage policy is out of scope; no connector in this repo queries one.

Not searched vs. not found: Not found — a second commercial payer's policy naming this domain's founding device specifically, beyond Aetna's. Not found — any Medicare Advantage plan or state Medicaid coverage document for this device category. Not searched to completion — Cigna's tinnitus-related coverage policy was located and its PDF fetched, but the retrieved bytes were not text-extractable in this environment (a compressed/encoded PDF stream), so nothing from it is reported; UnitedHealthcare's policy was searched for by name and not located at all. Not retrieved, not found-to-be-absent — NCD 50.6 ("Tinnitus Masking"): its existence and title were seen in search results, but its text was never fetched, because www.cms.gov returned HTTP 403 on the Medicare Coverage Database view page and on the direct National Coverage Determinations Manual PDF download, and a third-party mirror of the same PDF also failed to serve readable text. No claim from that NCD appears anywhere above. Not carried forward as a numbered source — a GSA eLibrary contractor lookup (retrieved 2026-09-01) showed an active Federal Supply Schedule 65 II A contract, Special Item Number A-34 ("Audiometer Equipment"), held by NEUROMOD USA INC., with a current option period running through 2029-05-14. This was independently retrieved, not merely found via search, and narrows the domain dossier's Section 6 gap (which had the VA/DoD channel sourced only to company press materials) — but the contract number itself matches none of this report's closed identifier forms (PMID, NCT, K-number, CFR section, HCPCS code, DOI, CELEX, FR Doc number), so it is recorded here rather than as a numbered source, and the contract's actual price list and terms remain unconfirmed by this pass.

[inference] The pattern across §3 — two independent payers denying a device-specific code, one payer's own bulletin naming this domain's founding device as not covered, and a general Medicare hearing-aid exclusion regulation confirmed live but not shown to name tinnitus devices specifically — is consistent with (but does not establish) a reimbursement landscape where commercial and Medicare channels currently treat this device category as self-pay by default, while a VA-specific statutory and procurement basis exists structurally regardless of the commercial pattern. This sentence is the writer's own synthesis of the sourced lines above, not a finding any single source states.

6. Claim Candidates